Moore RG, et al. - Given the difficulty in discriminating malignant from benign disease in woman with a pelvic mass which complicates the management of these cases, researchers investigated if an improvement in the detection of EOC could be achieved via adding biomarkers to HE4 and CA125, as used in the Risk of Malignancy Algorithm (ROMA). In this IRB approved prospective clinical trial including 184 women diagnosed with a pelvic mass who subsequently underwent surgery, a predictive value of the combination of HE4 and CA125 for ovarian cancer was identified. The detection of ovarian cancer was not improved significantly with additional markers to HE4 and CA125. Findings suggest HE4 and CA125 as complimentary biomarkers that perform best when used in combination.